Pharma

Your Article Summary

See Latest Articles

Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs
Current Medical Research and Opinion, 06/24/09

Borah BJ et al. – Study reports that etanercept (ETA) users had longer treatment duration, were more likely to adhere to their medication regimen and had lower rheumatoid arthritis (RA)-related pharmacy and RA-related total costs compared with adalimumab (ADA) users.

• Main objectives of study were:
  • To examine adherence to ADA and ETA and health care costs in RA pts, and
  • To explore the association between adherence, utilization and costs
• RA pts treated with etanercept or adalimumab during Jan 2005-Dec 2005 were identified
• Patient adherence and costs were assessed during the 1 yr post-index period (first dispensing date)
• Nonadherence was modeled using logistic regression
• Hazard ratios (HR) comparing time to discontinuation were estimated using Cox proportional hazard (PH) models

• Compared with ADA users, ETA users had longer average treatment duration
• Unadjusted adherence rates for naïve and existing users were 63% and 70% (ADA), and 65% and 73% (ETA)
• Compared with ETA users, ADA users were more likely to be nonadherent
• Existing ADA users were more likely to discontinue their medication than existing ETA users
• Compared with ADA users, ETA users had lower RA-related pharmacy costs and RA-related total costs

Today in Physician/Patient Trends...keeping you current

Receive free subspecialty "5-minute updates" via email

How important is intestinal cytochrome P450 3A metabolism
Trends in Pharmacological Sciences, 10/14/09

Evaluation of Vancomycin and Daptomycin Potency Trends against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006
Antimicrobial Agents and Chemotherapy, 10/09/09

Urinary Diversion Trends at a High Volume, Single American Tertiary Care Center
The Journal of Urology, 11/02/09

See All of Physician/Patient Trends